Results 61 to 70 of about 5,080,573 (227)

Synchronous pulmonary malignancies: atypical presentation of mantle cell lymphoma masking a lung malignancy

open access: yesRare Tumors, 2015
We present a case of a pleural space malignancy masked by an atypical presentation of mantle cell lymphoma. Our patient presented with a large pleural effusion and right sided pleural studding, initially attributed to a new diagnosis of mantle cell ...
Luke Masha   +2 more
doaj   +1 more source

Mantle cell lymphoma of the prostate

open access: yesCanadian Urological Association Journal, 2013
Lymphoma of the prostate, either primary or secondary, is veryrare. We report the case of an 82-year-old man with symptoms ofbladder outlet obstruction presumably due to benign prostatehyperplasia (BPH). He underwent an uneventful transurethral resectionof the prostate.
Abuhjar, Abdussalam, Ronald G, Gerridzen
openaire   +3 more sources

Human biomarker navigator

open access: yesiMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li   +29 more
wiley   +1 more source

NF-κB signaling and its relevance to the treatment of mantle cell lymphoma

open access: yesJournal of Hematology & Oncology, 2018
Mantle cell lymphoma is an aggressive subtype of non-Hodgkin B cell lymphoma that is characterized by a poor prognosis determined by Ki67 and Mantle Cell International Prognostic Index scores, but it is becoming increasingly treatable.
Swathi Balaji   +5 more
doaj   +1 more source

Recurrent mantle cell lymphoma in the uterine cervix: a case report

open access: yesJournal of Medical Case Reports, 2020
Background Mantle cell lymphoma is one of several subtypes of non-Hodgkin lymphoma. Cervical relapse of non-Hodgkin lymphoma is a very rare condition that has a variable and nonspecific presentation and may resemble other neoplastic or inflammatory ...
Giusi Santangelo   +10 more
doaj   +1 more source

Prime editing in neuropsychiatric disorders: From mutation‐specific target selection to clinical translation

open access: yesNeuroprotection, EarlyView.
Abstract Prime editing, a novel clustered regularly interspaced short palindromic repeats (CRISPR)‐based technology, fuses a reverse transcriptase (RT) to an engineered CRISPR‐associated protein 9 (Cas9) and uses a prime editing guide RNA (pegRNA)‐encoded template.
Tianshan Ji   +4 more
wiley   +1 more source

Radioimmunotherapy in mantle cell lymphoma [PDF]

open access: yesBest Practice & Research Clinical Haematology, 2012
Mantle cell lymphoma (MCL), though characterized by the chromosomal translocation t(11; 14) (q13; q32), is a heterogeneous disease. Often termed an aggressive lymphoma in the U.S., but included in indolent lymphoma trials in Europe, MCL is not curable with standard immuno-chemotherapy.
Alan P, Skarbnik, Mitchell R, Smith
openaire   +2 more sources

Nanomedicine applications in lymphoma: Advancing precision diagnostics, targeted therapeutics, and prospective developments

open access: yesVIEW, EarlyView.
Lymphoma is a group of blood cancers that can appear in lymph nodes, blood, bone marrow, spleen, liver, or the central nervous system, which makes drug delivery and disease monitoring difficult. This review summarizes how nanomedicine technologies may improve targeted treatment and imaging, while carefully separating approved or guideline‐supported ...
Mohd Ahmar Rauf   +5 more
wiley   +1 more source

Characteristics of follicular and mantle cell lymphoma in Brazil: prognostic impact of clinical parameters and treatment conditions in two hospitals

open access: yesHematology, Transfusion and Cell Therapy, 2018
Objective: Follicular and mantle cell lymphoma are low-grade B-cell malignancies that lack good responses to chemoimmunotherapy. This study aimed to assess retrospectively clinicopathological features and to determine independent prognostic factors for ...
Guilherme Rossi Assis-Mendonça   +8 more
doaj   +1 more source

Preliminary evidence of imaging of chemokine receptor-4-targeted PET/CT with [68Ga]pentixafor in non-Hodgkin lymphoma: comparison to [18F]FDG

open access: yesEJNMMI Research, 2020
Background In order to study the CXCR4 expression with [68Ga]pentixafor PET in different types of non-Hodgkin lymphoma, we performed a retrospective study to describe the [68Ga]pentixafor PET/CT imaging in a spectrum of lymphomas and to compare it with ...
Qingqing Pan   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy